Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.
about
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Response definition criteria for ELISPOT assays revisitedData analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.The immuno-oncology framework: Enabling a new era of cancer therapy.Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error.Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer stainingSelf-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyELISpot for measuring human immune responses to vaccines.Harmonization of immune biomarker assays for clinical studies.Standardized Serum-Free Cryomedia Maintain Peripheral Blood Mononuclear Cell Viability, Recovery, and Antigen-Specific T-Cell Response Compared to Fetal Calf Serum-Based MediumSerum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.Harmonization of the intracellular cytokine staining assay.Conference scene: Immune signatures in the tumor and beyond.
P2860
Q28744503-F6C4B97E-01F3-4C30-8598-5847AC82D19CQ30495664-6F1AAE0C-EE48-4F4D-BB4D-13602BE37DADQ30927297-E7F7AF9B-DF3C-4831-9476-FF7F63F9EA4BQ33601830-08403A73-A9EC-443D-9E41-2843418ADAEAQ34284462-21EF2F89-086C-4348-B92D-02EE2A7FEE1DQ34327212-775C429B-F2BC-4A2A-89EF-DA6AC9949003Q34402469-FF4DA287-0615-4BDD-A00D-D0B88E3A4C6FQ35746834-42FFA33C-5771-4FA7-A6F3-ADBFA776EA41Q37857243-02C8CE2B-F63A-4EBD-9B2A-7463ABB56B64Q37954593-16AAB131-81E4-4872-9A2C-71C47DE901C5Q38544409-0586A972-C6BB-47F4-BE78-A7B7B95D0F93Q39784050-F27D61C9-E8E1-4606-AA6A-04429CBC849EQ41550516-33BA9C40-B0CD-4407-8353-C89230D2BA81Q42207308-EB532DD8-D62C-4E0B-B444-415183B362B4Q50914423-C4D854A5-30AA-4044-8734-D445E32BBE3D
P2860
Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Serum is not required for ex v ...... an CIMT Immunoguiding Program.
@ast
Serum is not required for ex v ...... an CIMT Immunoguiding Program.
@en
type
label
Serum is not required for ex v ...... an CIMT Immunoguiding Program.
@ast
Serum is not required for ex v ...... an CIMT Immunoguiding Program.
@en
prefLabel
Serum is not required for ex v ...... an CIMT Immunoguiding Program.
@ast
Serum is not required for ex v ...... an CIMT Immunoguiding Program.
@en
P2093
P2860
P1476
Serum is not required for ex v ...... ean CIMT Immunoguiding Program
@en
P2093
C Gouttefangeas
C M Britten
M J P Welters
S H van der Burg
P2860
P2888
P304
P356
10.1007/S00262-009-0814-4
P577
2010-01-06T00:00:00Z
P5875
P6179
1021429898